This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Indoleamine 2,3-dioxygenase 1 (IDO1)	<p>Mouse and cell culture studies identified IDO1 inhibitors derived from the natural compound tryptanthrin that could be useful for treating cancer. In culture, compounds in the series inhibited IDO1 and reversed IDO1-mediated suppression of T lymphocytes. In a mouse model of Lewis lung carcinoma, the lead compound decreased tumor growth and immunosuppressive T_{reg} cell numbers compared with vehicle. Next steps could include testing the lead inhibitor in combination with other cancer therapeutics in animal models.</p> <p>NewLink Genetics Corp.'s IDO (INDO) pathway inhibitor, NLG8189, is in Phase I/II testing to treat solid tumors.</p> <p>Incyte Corp.'s IDO1 inhibitor, INCB24360, is in Phase II testing to treat solid tumors.</p> <p>SciBX 6(44); doi:10.1038/scibx.2013.1252 Published online Nov. 14, 2013</p>	Patent and licensing status unavailable	<p>Yang, S. <i>et al. J. Med. Chem.</i>; published online Oct. 7, 2013; doi:10.1021/jm401195n</p> <p>Contact: Qing Yang, Fudan University, Shanghai, China e-mail: yangqing68@fudan.edu.cn</p>